Cell signaling news
Here we present recent news items specially selected from Nature, Nature Medicine and Nature Biotechnology.
January 2004
2004:
December |
November |
October |
September |
August |
July |
June |
May |
April |
March |
February |
January
Other years: 2002 | 2003 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010
News | News in brief | News Features
News
African labs win major role in tsetse-fly genome project
An international research consortium has been formed to sequence the genome of the tsetse-fly, the pest that carries disease to millions of people and cattle in Africa.
Nature (29 January 2004)
| Full Text |
NIH acts to quench 'conflict of interest' allegations
The National Institutes of Health looks set to ensure fuller disclosure of dealings that its senior staff have with private companies.
Nature (29 January 2004)
| Full Text |
Director quits as cash cutbacks hit Californian labs
The California Institutes for Science and Innovation – four high-profile interdisciplinary facilities built at a cost of $400 million – are going through a turbulent time just months before researchers move into the new buildings.
Nature (21 January 2004)
| Full Text |
Ministers prepare to back neuroscience network
Brain scientists around the world wrestling with the thorny problem of how to share their data should soon find their lives getting a little easier.
Nature (21 January 2004)
| Full Text |
Europe's researchers up in arms over clinical-trial rules
Some 2,000 clinical researchers have signed an Internet petition calling for changes to proposed new European Union rules on patient trials. They say that, as the revised rules stand, they would place immense bureaucratic burdens on their backs.
Nature (21 January 2004)
| Full Text |
Intelligence law draws fire over NSF security project
The US Congress has told the National Science Foundation (NSF) to coordinate research on intelligence matters. But critics say that if the research agency acts as instructed, it will violate its tradition of openly disseminated science.
Nature (15 January 2004)
| Full Text |
Europe warned against research council
The Royal Society has poured cold water on plans to create a central funding body for science in Europe.
Nature (15 January 2004)
| Full Text |
Antibodies to SARS-like virus hint at repeated infections
A virus similar to that responsible for severe acute respiratory syndrome (SARS) infected people in Hong Kong 18 months before SARS reared its head, a recent study says. But some experts say the result is tentative and needs to be confirmed by larger studies.
Nature (15 January 2004)
| Full Text |
India targets local HIV strain in test of AIDS vaccine
India is gearing up to test an AIDS vaccine targeted at its most prevalent strain of HIV for the first time. Safety trials of the vaccine are expected to begin this summer.
Nature (15 January 2004)
| Full Text |
Neglected diseases brought in from the cold
The European Commission is launching an ambitious programme to study a group of rare, mostly untreatable, genetic diseases that have so far attracted little attention from research agencies.
Nature (15 January 2004)
| Full Text |
Ethics accusations spark rapid reaction from NIH chief
The US National Institutes of Health (NIH) will act immediately to address concerns that its ethics standards are not rigorous enough, its director, Elias Zerhouni, has told Congress.
Nature (15 January 2004)
| Full Text |
Swift response greets return of SARS in China
China is rushing to quell public fears after confirmation on 5 January of the first naturally acquired case of SARS since the disease was contained in July last year.
Nature (8 January 2004)
| Full Text |
Geneticists chip away at unruly data
Researchers in genetics trying to share their results face an uphill struggle. The wide range of experimental methods that they use makes it fiendishly hard to compare data.
Nature (8 January 2004)
| Full Text |
Canadian prime minister makes science a priority
Scientists in Canada are feeling a rush of optimism over the words and actions of the new prime minister, Paul Martin, who says that if he was born again, he'd like to come back as a basic researcher.
Nature (8 January 2004)
| Full Text |
Halted trial renews questions about cancer vaccines
Citing ethics violations and 'important flaws' in methodology, Swiss authorities have ended a much-heralded cancer vaccine trial at Zürich University and will allow a second trial to continue only after the errors have been corrected.
Nature Medicine (January 2004)
| Full Text |
AIDS infections, deaths hit record high in 2003
More people became infected with HIV and died from AIDS in 2003 than ever before, according to a new report from the United Nations.
Nature Medicine (January 2004)
| Full Text |
Legal battle threatens universities' use of patented technologies
Duke University researchers have been asked to review their use of patented research technologies and use alternative approaches wherever possible.
Nature Medicine (January 2004)
| Full Text |
New vaccines enter fray in fight against tuberculosis
The global effort to eradicate tuberculosis may soon gain the tools to succeed. New TB vaccine candidates—the first in more than 80 years—are now in phase 1 clinical trials.
Nature Medicine (January 2004)
| Full Text |
Antibiotic resistance soars in Europe
Responding to "worrying trends" in antimicrobial resistance in Europe, the European Union has announced two new projects, totaling $16 million, to study how resistance arises.
Nature Medicine (January 2004)
| Full Text |
2003: The good, the bad and the unexpected
Highlights of some of the research developments for 2003.
Nature Medicine (January 2004)
| Full Text |
Profile: Marc Tessier-Lavigne
How do you top solving a century-old riddle in developmental neurobiology? By moving to a company with no commercial interest in neuroscience. For someone as ambitious as Marc Tessier-Lavigne, leaving academia for the biotech giant Genentech could be the right choice.
Nature Medicine (January 2004)
| Full Text |
China approves first gene therapy
China became the first country to approve the commercial production of a gene therapy, and it is due to hit the market in early January.
Nature Biotechnology (January 2004)
| Full Text |
UK to pursue contract clinical trials
A report presented to the UK government proposes to streamline clinical trials offered through the country's health system, the National Health Service, to provide local biotech companies with a competitive advantage and put the country on the map of clinical trials providers.
Nature Biotechnology (January 2004)
| Full Text |
Cancer trials get set for biomarkers
The use of biomarkers in clinical trials is slowly becoming a reality that the US Food and Drug Administration has begun to recognize. But standards need to be agreed upon for what determines the validity of a biomarker before any can be used in the drug regulatory process.
Nature Biotechnology (January 2004)
| Full Text |
News in brief
Cambridge abandons primate centre plan as security costs rocket
| Germany goes for gold to bolster science funding
| Congress boosts defence and security in 2004 budget
| US medical biodefence agency proposed
| Coordinated effort aims to eradicate polio
| China's human-cloning policy fudges law on cross-species fusions
| DNA-theft bill stores up trouble for research
| Academy set up to boost Texan science
| Germany aims high to create élite university
| Japan agrees to hand over espionage suspect
| Stem-cell centres get green light in Spain
| US to test pediatric drugs
| Europe to back some stem cell research
| China approves world's first gene therapy drug
| Ebola rears ugly head as vaccine enters trials
| Brain drain in Europe
| ES cell vote stalled
| Dutch genomics boosted
| Lilly buys AME
| Antibiotics merger
News Features
Brain development: The most important sexual organ
New evidence suggests that the brain begins to develop differently in males and females much earlier than was thought – before sex hormones come into play.
Nature (29 January 2004)
| Full Text |
Signal transduction inhibitors – a work in progress
Is the race to take protein kinase inhibitors to market compromising their success in the clinic?
Nature Biotechnology (January 2004)
| Full Text |
As one door closes...
Immigration controls introduced under the 'war on terror' are restricting the flow of foreign researchers into the United States. With other countries moving in on this pool of talent, will the balance of scientific power shift?
Nature (15 January 2004)
| Full Text |
Hungarian science: Dreaming on the Danube
Can Budapest regain its status as one of Europe's scientific hubs? Perhaps, if the generation gap between Soviet-era scientists and young, westward-looking researchers can be bridged.
Nature (08 January 2004)
| Full Text |
|
